BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37635919)

  • 1. Simultaneous Imaging of Ga-DOTA-TATE and Lu-DOTA-TATE in Murine Models of Neuroblastoma.
    Zheng Y; Huh Y; Vetter K; Nasholm N; Gustafson C; Seo Y
    IEEE Trans Radiat Plasma Med Sci; 2023 Jan; 7(1):75-82. PubMed ID: 37635919
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.
    Zhang L; Vines DC; Scollard DA; McKee T; Komal T; Ganguly M; Do T; Wu B; Alexander N; Vali R; Shammas A; Besanger T; Baruchel S
    Contrast Media Mol Imaging; 2017; 2017():9481276. PubMed ID: 29097943
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
    Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between uptake of [
    Stenvall A; Gustafsson J; Larsson E; Roth D; Sundlöv A; Jönsson L; Hindorf C; Ohlsson T; Sjögreen Gleisner K
    EJNMMI Res; 2022 Dec; 12(1):75. PubMed ID: 36534192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
    Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between [
    Bruvoll R; Blakkisrud J; Mikalsen LT; Connelly J; Stokke C
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
    Velikyan I; Xu H; Nair M; Hall H
    Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors.
    Zellmer J; Yen HY; Kaiser L; Gildehaus FJ; Böning G; Steiger K; Hacker M; Bartenstein P; Todica A; Haug AR; Ilhan H
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implementation of PLANET® Dose for dosimetric assessment after [
    Santoro L; Pitalot L; Trauchessec D; Mora-Ramirez E; Kotzki PO; Bardiès M; Deshayes E
    EJNMMI Res; 2021 Jan; 11(1):1. PubMed ID: 33394212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
    Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Thakur S; Daley B; Millo C; Cochran C; Jacobson O; Lu H; Wang Z; Kiesewetter D; Chen X; Vasko V; Klubo-Gwiezdzinska J
    Clin Cancer Res; 2021 Mar; 27(5):1399-1409. PubMed ID: 33355247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
    Wehrmann C; Senftleben S; Zachert C; Müller D; Baum RP
    Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological Biodistribution of
    Özgüven S; Filizoğlu N; Kesim S; Öksüzoğlu K; Şen F; Öneş T; İnanır S; Turoğlu HT; Erdil TY
    Mol Imaging Radionucl Ther; 2021 Feb; 30(1):39-46. PubMed ID: 33586406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
    Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
    Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of [
    Ha S; Kim YI; Oh JS; Yoo C; Ryoo BY; Ryu JS
    EJNMMI Phys; 2024 Feb; 11(1):14. PubMed ID: 38315270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary PET/CT Imaging with Somatostatin Analogs [
    Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
    Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.